| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dementia | 15 | 2021 | 488 | 2.390 |
Why?
|
| Medicare | 20 | 2025 | 463 | 2.040 |
Why?
|
| Comparative Effectiveness Research | 5 | 2012 | 77 | 1.380 |
Why?
|
| Hypertension | 10 | 2023 | 1396 | 1.330 |
Why?
|
| Aged | 89 | 2025 | 21640 | 1.260 |
Why?
|
| Retrospective Studies | 71 | 2025 | 17403 | 1.250 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 6 | 2023 | 226 | 1.240 |
Why?
|
| United States | 68 | 2025 | 11682 | 1.230 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2022 | 757 | 1.190 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2023 | 610 | 1.150 |
Why?
|
| Heart Failure | 17 | 2016 | 2423 | 1.070 |
Why?
|
| Breast Neoplasms | 5 | 2023 | 2765 | 1.030 |
Why?
|
| SEER Program | 3 | 2024 | 224 | 1.000 |
Why?
|
| Practice Patterns, Physicians' | 8 | 2018 | 765 | 0.980 |
Why?
|
| Antipsychotic Agents | 12 | 2021 | 388 | 0.980 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2025 | 1414 | 0.970 |
Why?
|
| Risk | 14 | 2017 | 834 | 0.950 |
Why?
|
| Angiotensin Receptor Antagonists | 5 | 2023 | 138 | 0.940 |
Why?
|
| United States Department of Veterans Affairs | 10 | 2012 | 703 | 0.930 |
Why?
|
| Cholinergic Antagonists | 7 | 2019 | 54 | 0.880 |
Why?
|
| Proportional Hazards Models | 11 | 2019 | 1485 | 0.870 |
Why?
|
| Prescription Drugs | 5 | 2019 | 58 | 0.840 |
Why?
|
| Antihypertensive Agents | 5 | 2012 | 410 | 0.800 |
Why?
|
| Diabetes Mellitus | 13 | 2023 | 934 | 0.780 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 276 | 0.750 |
Why?
|
| Economics, Pharmaceutical | 3 | 2009 | 9 | 0.730 |
Why?
|
| Aged, 80 and over | 33 | 2024 | 7173 | 0.730 |
Why?
|
| Hospitals, Veterans | 17 | 2007 | 357 | 0.730 |
Why?
|
| Motivational Interviewing | 4 | 2023 | 52 | 0.710 |
Why?
|
| Databases, Factual | 11 | 2024 | 1241 | 0.710 |
Why?
|
| Depression | 12 | 2020 | 1355 | 0.690 |
Why?
|
| Comorbidity | 16 | 2020 | 1619 | 0.690 |
Why?
|
| Urinary Bladder, Overactive | 4 | 2021 | 31 | 0.680 |
Why?
|
| Hyperlipidemias | 4 | 2022 | 198 | 0.680 |
Why?
|
| Female | 87 | 2025 | 71541 | 0.680 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 377 | 0.680 |
Why?
|
| Metformin | 1 | 2022 | 165 | 0.680 |
Why?
|
| Cohort Studies | 29 | 2022 | 5189 | 0.660 |
Why?
|
| Selection Bias | 2 | 2009 | 22 | 0.650 |
Why?
|
| Humans | 123 | 2025 | 133552 | 0.640 |
Why?
|
| Nursing Homes | 11 | 2019 | 97 | 0.630 |
Why?
|
| Cardiovascular Diseases | 6 | 2023 | 2090 | 0.630 |
Why?
|
| Male | 84 | 2025 | 65790 | 0.600 |
Why?
|
| Dyslipidemias | 2 | 2015 | 244 | 0.590 |
Why?
|
| Risk Adjustment | 5 | 2015 | 60 | 0.590 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2019 | 231 | 0.560 |
Why?
|
| Medicare Part C | 5 | 2023 | 39 | 0.550 |
Why?
|
| Risk Assessment | 8 | 2016 | 3700 | 0.550 |
Why?
|
| Medicare Part D | 4 | 2020 | 17 | 0.540 |
Why?
|
| Epidemiologic Research Design | 1 | 2016 | 8 | 0.510 |
Why?
|
| Paroxetine | 4 | 2017 | 29 | 0.510 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 1787 | 0.500 |
Why?
|
| Proton Pump Inhibitors | 1 | 2019 | 285 | 0.490 |
Why?
|
| Middle Aged | 51 | 2025 | 29262 | 0.490 |
Why?
|
| Veterans | 11 | 2011 | 1768 | 0.480 |
Why?
|
| Gastroesophageal Reflux | 1 | 2019 | 336 | 0.480 |
Why?
|
| Odds Ratio | 5 | 2016 | 1336 | 0.470 |
Why?
|
| Receptor, ErbB-2 | 3 | 2023 | 559 | 0.460 |
Why?
|
| Medication Adherence | 7 | 2025 | 339 | 0.450 |
Why?
|
| Multivariate Analysis | 14 | 2016 | 1490 | 0.450 |
Why?
|
| Longitudinal Studies | 7 | 2021 | 1494 | 0.430 |
Why?
|
| Drug Utilization Review | 3 | 2019 | 33 | 0.420 |
Why?
|
| Logistic Models | 16 | 2017 | 1907 | 0.400 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 1351 | 0.400 |
Why?
|
| Managed Care Programs | 3 | 2022 | 61 | 0.400 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2023 | 67 | 0.390 |
Why?
|
| Hypoglycemic Agents | 3 | 2025 | 488 | 0.380 |
Why?
|
| Anti-Obesity Agents | 1 | 2012 | 45 | 0.380 |
Why?
|
| Antirheumatic Agents | 2 | 2023 | 124 | 0.370 |
Why?
|
| Losartan | 1 | 2011 | 36 | 0.360 |
Why?
|
| Biphenyl Compounds | 1 | 2011 | 62 | 0.360 |
Why?
|
| Tetrazoles | 1 | 2011 | 64 | 0.360 |
Why?
|
| Valine | 1 | 2011 | 116 | 0.350 |
Why?
|
| Pneumonia | 3 | 2020 | 342 | 0.340 |
Why?
|
| Benzimidazoles | 1 | 2011 | 136 | 0.340 |
Why?
|
| Case-Control Studies | 14 | 2023 | 3648 | 0.340 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2023 | 294 | 0.330 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2009 | 10 | 0.320 |
Why?
|
| Neoplasms | 3 | 2020 | 3027 | 0.320 |
Why?
|
| Quality Indicators, Health Care | 3 | 2019 | 232 | 0.320 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 201 | 0.320 |
Why?
|
| Angioplasty | 2 | 2007 | 80 | 0.310 |
Why?
|
| Risk Factors | 23 | 2017 | 11098 | 0.310 |
Why?
|
| Survival Rate | 5 | 2023 | 2211 | 0.310 |
Why?
|
| Pharmaceutical Services | 1 | 2009 | 38 | 0.310 |
Why?
|
| Incidence | 15 | 2019 | 3399 | 0.300 |
Why?
|
| Data Interpretation, Statistical | 4 | 2011 | 239 | 0.300 |
Why?
|
| Aortic Aneurysm, Abdominal | 4 | 2007 | 445 | 0.300 |
Why?
|
| Baths | 2 | 2020 | 16 | 0.300 |
Why?
|
| Elective Surgical Procedures | 3 | 2007 | 168 | 0.290 |
Why?
|
| Multiple Sclerosis | 2 | 2023 | 392 | 0.290 |
Why?
|
| Propensity Score | 7 | 2017 | 258 | 0.290 |
Why?
|
| Research | 3 | 2023 | 272 | 0.290 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2020 | 69 | 0.280 |
Why?
|
| Health Expenditures | 3 | 2018 | 116 | 0.280 |
Why?
|
| Prescription Drug Monitoring Programs | 2 | 2017 | 9 | 0.280 |
Why?
|
| Treatment Outcome | 13 | 2023 | 12988 | 0.280 |
Why?
|
| Accidental Falls | 3 | 2016 | 120 | 0.280 |
Why?
|
| Drug Utilization | 3 | 2020 | 166 | 0.270 |
Why?
|
| Diuretics | 2 | 2005 | 169 | 0.270 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2006 | 315 | 0.270 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 479 | 0.270 |
Why?
|
| Leptospirosis | 1 | 2006 | 6 | 0.270 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2022 | 102 | 0.260 |
Why?
|
| Quality of Health Care | 5 | 2005 | 420 | 0.260 |
Why?
|
| Fractures, Bone | 3 | 2016 | 212 | 0.260 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2017 | 285 | 0.260 |
Why?
|
| Dog Diseases | 1 | 2006 | 60 | 0.250 |
Why?
|
| Varenicline | 2 | 2016 | 14 | 0.250 |
Why?
|
| Data Collection | 3 | 2016 | 396 | 0.250 |
Why?
|
| Bupropion | 2 | 2016 | 30 | 0.250 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2016 | 38 | 0.250 |
Why?
|
| Adult | 30 | 2024 | 31833 | 0.240 |
Why?
|
| Inappropriate Prescribing | 2 | 2015 | 36 | 0.240 |
Why?
|
| Ethical Review | 1 | 2005 | 3 | 0.240 |
Why?
|
| Drug Therapy, Combination | 6 | 2025 | 1197 | 0.240 |
Why?
|
| Hospitalization | 10 | 2012 | 1892 | 0.230 |
Why?
|
| Ethics Committees, Research | 1 | 2005 | 33 | 0.230 |
Why?
|
| Diabetic Angiopathies | 1 | 2005 | 72 | 0.230 |
Why?
|
| Analgesics, Opioid | 3 | 2019 | 463 | 0.230 |
Why?
|
| Cross Infection | 2 | 2020 | 333 | 0.230 |
Why?
|
| Human Experimentation | 1 | 2005 | 36 | 0.230 |
Why?
|
| Medicaid | 5 | 2025 | 254 | 0.230 |
Why?
|
| Fingolimod Hydrochloride | 2 | 2023 | 37 | 0.230 |
Why?
|
| Opiate Substitution Treatment | 1 | 2024 | 30 | 0.230 |
Why?
|
| Internationality | 3 | 2009 | 138 | 0.230 |
Why?
|
| Alzheimer Disease | 3 | 2022 | 875 | 0.230 |
Why?
|
| Outpatients | 1 | 2006 | 267 | 0.220 |
Why?
|
| Drug Prescriptions | 3 | 2019 | 237 | 0.220 |
Why?
|
| Methadone | 1 | 2024 | 126 | 0.220 |
Why?
|
| Obesity | 2 | 2015 | 2429 | 0.220 |
Why?
|
| Polypharmacy | 3 | 2019 | 39 | 0.220 |
Why?
|
| Smoking Cessation | 2 | 2016 | 209 | 0.220 |
Why?
|
| Homes for the Aged | 4 | 2017 | 25 | 0.220 |
Why?
|
| Focus Groups | 1 | 2024 | 211 | 0.210 |
Why?
|
| Workload | 1 | 2005 | 151 | 0.210 |
Why?
|
| Cognitive Dysfunction | 2 | 2019 | 313 | 0.210 |
Why?
|
| Psychotic Disorders | 3 | 2010 | 149 | 0.210 |
Why?
|
| Education, Pharmacy | 1 | 2024 | 61 | 0.200 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2023 | 50 | 0.200 |
Why?
|
| Decision Making | 4 | 2009 | 699 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2010 | 870 | 0.190 |
Why?
|
| Benzodiazepines | 4 | 2017 | 111 | 0.190 |
Why?
|
| Parkinson Disease | 2 | 2020 | 734 | 0.190 |
Why?
|
| Surgery Department, Hospital | 1 | 2002 | 22 | 0.190 |
Why?
|
| Postmenopause | 1 | 2022 | 155 | 0.180 |
Why?
|
| Cross-Sectional Studies | 9 | 2020 | 3739 | 0.180 |
Why?
|
| Hospital Mortality | 3 | 2015 | 1088 | 0.180 |
Why?
|
| Opioid-Related Disorders | 1 | 2024 | 282 | 0.180 |
Why?
|
| Medication Errors | 2 | 2015 | 206 | 0.180 |
Why?
|
| Biological Products | 1 | 2023 | 137 | 0.180 |
Why?
|
| Drug Interactions | 2 | 2019 | 261 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2023 | 1139 | 0.180 |
Why?
|
| Health Status | 3 | 2016 | 412 | 0.170 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2020 | 204 | 0.170 |
Why?
|
| Muscarinic Antagonists | 4 | 2021 | 38 | 0.170 |
Why?
|
| Chlorhexidine | 2 | 2020 | 47 | 0.170 |
Why?
|
| Depressive Disorder | 3 | 2015 | 485 | 0.170 |
Why?
|
| Intensive Care Units | 4 | 2020 | 537 | 0.170 |
Why?
|
| Cognition | 2 | 2015 | 814 | 0.170 |
Why?
|
| Health Maintenance Organizations | 3 | 2009 | 24 | 0.170 |
Why?
|
| Decision Support Techniques | 2 | 2016 | 318 | 0.170 |
Why?
|
| Psychotropic Drugs | 2 | 2019 | 130 | 0.160 |
Why?
|
| Advisory Committees | 2 | 2011 | 158 | 0.160 |
Why?
|
| Health Care Costs | 1 | 2003 | 406 | 0.160 |
Why?
|
| Chronic Disease | 2 | 2016 | 1255 | 0.160 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 648 | 0.150 |
Why?
|
| Electronic Health Records | 2 | 2020 | 792 | 0.150 |
Why?
|
| Deprescriptions | 1 | 2019 | 12 | 0.150 |
Why?
|
| Lipids | 1 | 2022 | 567 | 0.150 |
Why?
|
| Patient Readmission | 4 | 2016 | 416 | 0.150 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2019 | 54 | 0.150 |
Why?
|
| Models, Statistical | 3 | 2015 | 505 | 0.150 |
Why?
|
| Information Storage and Retrieval | 1 | 2019 | 64 | 0.150 |
Why?
|
| Drug Industry | 1 | 2018 | 48 | 0.140 |
Why?
|
| Peptic Ulcer | 1 | 2019 | 151 | 0.140 |
Why?
|
| Coronary Artery Bypass | 1 | 2002 | 532 | 0.140 |
Why?
|
| Health Services Research | 3 | 2002 | 189 | 0.140 |
Why?
|
| Diabetes Complications | 4 | 2010 | 206 | 0.140 |
Why?
|
| Texas | 7 | 2023 | 3693 | 0.140 |
Why?
|
| Prescription Drug Misuse | 1 | 2017 | 9 | 0.140 |
Why?
|
| Drug Costs | 1 | 2018 | 66 | 0.140 |
Why?
|
| Controlled Substances | 1 | 2017 | 12 | 0.140 |
Why?
|
| Health Policy | 2 | 2009 | 232 | 0.130 |
Why?
|
| Patient Discharge | 4 | 2016 | 517 | 0.130 |
Why?
|
| Prospective Studies | 9 | 2019 | 6575 | 0.130 |
Why?
|
| Patient Discharge Summaries | 1 | 2016 | 9 | 0.130 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 25 | 0.130 |
Why?
|
| Age Factors | 6 | 2015 | 2988 | 0.130 |
Why?
|
| Regression Analysis | 2 | 2009 | 825 | 0.130 |
Why?
|
| Critical Care | 2 | 2020 | 693 | 0.120 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2015 | 37 | 0.120 |
Why?
|
| Nicotinic Agonists | 1 | 2015 | 45 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 2511 | 0.120 |
Why?
|
| Southeastern United States | 2 | 2006 | 40 | 0.120 |
Why?
|
| Hip Fractures | 1 | 2016 | 74 | 0.120 |
Why?
|
| Tobacco Use Disorder | 1 | 2016 | 98 | 0.120 |
Why?
|
| Health Services Administration | 2 | 2005 | 11 | 0.120 |
Why?
|
| Diagnosis-Related Groups | 1 | 1995 | 27 | 0.120 |
Why?
|
| Palliative Care | 1 | 2019 | 461 | 0.120 |
Why?
|
| Physicians | 2 | 2019 | 633 | 0.120 |
Why?
|
| Hospital Information Systems | 1 | 1995 | 46 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 383 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 394 | 0.110 |
Why?
|
| Methotrexate | 3 | 2023 | 355 | 0.110 |
Why?
|
| Residence Characteristics | 3 | 2012 | 292 | 0.110 |
Why?
|
| Health Services Needs and Demand | 2 | 2015 | 179 | 0.110 |
Why?
|
| Colistin | 1 | 2014 | 33 | 0.110 |
Why?
|
| Emergency Service, Hospital | 3 | 2019 | 1152 | 0.110 |
Why?
|
| Causality | 2 | 2015 | 94 | 0.110 |
Why?
|
| Lung Diseases, Obstructive | 7 | 1999 | 34 | 0.110 |
Why?
|
| Central Nervous System Stimulants | 1 | 2014 | 130 | 0.110 |
Why?
|
| Health Personnel | 1 | 2019 | 540 | 0.110 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2014 | 88 | 0.110 |
Why?
|
| Community-Acquired Infections | 1 | 2016 | 247 | 0.110 |
Why?
|
| Health Resources | 1 | 1995 | 126 | 0.110 |
Why?
|
| Research Design | 2 | 2011 | 746 | 0.110 |
Why?
|
| Administration, Oral | 3 | 2021 | 727 | 0.110 |
Why?
|
| Evidence-Based Medicine | 2 | 2009 | 678 | 0.110 |
Why?
|
| Prevalence | 5 | 2017 | 2658 | 0.110 |
Why?
|
| Health Care Surveys | 2 | 2012 | 293 | 0.110 |
Why?
|
| Socioeconomic Factors | 3 | 2015 | 920 | 0.100 |
Why?
|
| Dementia, Vascular | 2 | 2010 | 17 | 0.100 |
Why?
|
| Weight Gain | 1 | 2016 | 412 | 0.100 |
Why?
|
| Mortality | 1 | 2015 | 262 | 0.100 |
Why?
|
| HIV Seroprevalence | 1 | 1992 | 9 | 0.100 |
Why?
|
| Observation | 2 | 2010 | 45 | 0.100 |
Why?
|
| Anxiety Disorders | 2 | 2009 | 728 | 0.100 |
Why?
|
| Mental Disorders | 2 | 2019 | 886 | 0.100 |
Why?
|
| California | 3 | 2006 | 143 | 0.100 |
Why?
|
| Substance-Related Disorders | 1 | 2017 | 489 | 0.100 |
Why?
|
| Sterilization, Tubal | 1 | 1992 | 17 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1190 | 0.100 |
Why?
|
| Housing | 1 | 2012 | 54 | 0.100 |
Why?
|
| Galantamine | 2 | 2022 | 11 | 0.100 |
Why?
|
| Rivastigmine | 2 | 2022 | 18 | 0.100 |
Why?
|
| Blood Vessels | 1 | 2012 | 108 | 0.100 |
Why?
|
| Nonlinear Dynamics | 1 | 2012 | 53 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 3 | 2007 | 222 | 0.100 |
Why?
|
| Sex Factors | 2 | 2015 | 1384 | 0.090 |
Why?
|
| Phenylcarbamates | 2 | 2022 | 16 | 0.090 |
Why?
|
| Hospitals | 1 | 1995 | 429 | 0.090 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2014 | 237 | 0.090 |
Why?
|
| Drug Therapy | 2 | 2010 | 93 | 0.090 |
Why?
|
| Models, Structural | 1 | 2011 | 50 | 0.090 |
Why?
|
| Valsartan | 1 | 2011 | 23 | 0.090 |
Why?
|
| Fosinopril | 1 | 2011 | 3 | 0.090 |
Why?
|
| Lisinopril | 1 | 2011 | 23 | 0.090 |
Why?
|
| Enalapril | 1 | 2011 | 14 | 0.090 |
Why?
|
| Captopril | 1 | 2011 | 27 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2016 | 3030 | 0.090 |
Why?
|
| Indans | 2 | 2022 | 56 | 0.090 |
Why?
|
| Medication Systems, Hospital | 1 | 2011 | 46 | 0.090 |
Why?
|
| Adolescent | 11 | 2023 | 20518 | 0.090 |
Why?
|
| Students, Pharmacy | 2 | 2024 | 71 | 0.090 |
Why?
|
| Leg | 2 | 2002 | 156 | 0.090 |
Why?
|
| Pseudomonas Infections | 1 | 2011 | 121 | 0.090 |
Why?
|
| Nurses | 1 | 2011 | 75 | 0.080 |
Why?
|
| Blood Glucose | 2 | 2025 | 1194 | 0.080 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2011 | 177 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 1850 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 2297 | 0.080 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 5461 | 0.080 |
Why?
|
| Smoking | 1 | 2015 | 1139 | 0.080 |
Why?
|
| Piperidines | 2 | 2022 | 239 | 0.080 |
Why?
|
| Fee-for-Service Plans | 1 | 2009 | 19 | 0.080 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 110 | 0.080 |
Why?
|
| Cerebrovascular Disorders | 1 | 2010 | 126 | 0.080 |
Why?
|
| Young Adult | 6 | 2024 | 9869 | 0.080 |
Why?
|
| Vascular Surgical Procedures | 2 | 2007 | 559 | 0.080 |
Why?
|
| Sick Role | 1 | 2009 | 32 | 0.080 |
Why?
|
| Poverty | 1 | 1992 | 437 | 0.080 |
Why?
|
| Somatoform Disorders | 1 | 2009 | 46 | 0.070 |
Why?
|
| Insurance Coverage | 1 | 2009 | 124 | 0.070 |
Why?
|
| Cost of Illness | 1 | 2010 | 275 | 0.070 |
Why?
|
| Immunosuppressive Agents | 2 | 2023 | 695 | 0.070 |
Why?
|
| ROC Curve | 1 | 2009 | 609 | 0.070 |
Why?
|
| Bacteremia | 1 | 2011 | 418 | 0.070 |
Why?
|
| Iatrogenic Disease | 2 | 1999 | 132 | 0.070 |
Why?
|
| Kidney | 1 | 2014 | 1418 | 0.070 |
Why?
|
| Demography | 2 | 2006 | 247 | 0.070 |
Why?
|
| Quetiapine Fumarate | 3 | 2012 | 17 | 0.070 |
Why?
|
| Dibenzothiazepines | 3 | 2012 | 15 | 0.070 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2011 | 541 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2009 | 1596 | 0.070 |
Why?
|
| Risperidone | 3 | 2012 | 60 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 54 | 0.060 |
Why?
|
| Ambulatory Care | 1 | 2009 | 413 | 0.060 |
Why?
|
| Myocardial Ischemia | 1 | 2009 | 365 | 0.060 |
Why?
|
| Quality of Life | 1 | 2016 | 2147 | 0.060 |
Why?
|
| Environment | 1 | 2006 | 156 | 0.060 |
Why?
|
| Time Factors | 5 | 2016 | 6577 | 0.060 |
Why?
|
| Dogs | 1 | 2006 | 798 | 0.060 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2010 | 637 | 0.060 |
Why?
|
| Oklahoma | 1 | 2004 | 9 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 1 | 2005 | 261 | 0.060 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 332 | 0.060 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2005 | 140 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2009 | 1211 | 0.060 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2005 | 172 | 0.060 |
Why?
|
| Hypolipidemic Agents | 1 | 2006 | 187 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2010 | 676 | 0.050 |
Why?
|
| Narcotic Antagonists | 1 | 2024 | 112 | 0.050 |
Why?
|
| Buprenorphine | 1 | 2024 | 100 | 0.050 |
Why?
|
| Crotonates | 1 | 2023 | 7 | 0.050 |
Why?
|
| Dimethyl Fumarate | 1 | 2023 | 11 | 0.050 |
Why?
|
| Potassium Deficiency | 1 | 2003 | 12 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2005 | 417 | 0.050 |
Why?
|
| Netherlands | 1 | 2003 | 47 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2005 | 190 | 0.050 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2011 | 680 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2024 | 330 | 0.050 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2005 | 365 | 0.050 |
Why?
|
| Policy Making | 1 | 2003 | 62 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 650 | 0.050 |
Why?
|
| Primary Health Care | 1 | 2009 | 794 | 0.050 |
Why?
|
| Pressure Ulcer | 1 | 2003 | 79 | 0.050 |
Why?
|
| Tolterodine Tartrate | 1 | 2021 | 3 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 3977 | 0.050 |
Why?
|
| Linear Models | 3 | 2016 | 722 | 0.050 |
Why?
|
| Educational Measurement | 1 | 2024 | 338 | 0.040 |
Why?
|
| Acetylcholinesterase | 1 | 2021 | 26 | 0.040 |
Why?
|
| Forecasting | 1 | 2003 | 376 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2024 | 631 | 0.040 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2002 | 129 | 0.040 |
Why?
|
| Benchmarking | 1 | 2002 | 146 | 0.040 |
Why?
|
| Injections | 1 | 2021 | 156 | 0.040 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 21 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2023 | 401 | 0.040 |
Why?
|
| Brain | 1 | 2012 | 3225 | 0.040 |
Why?
|
| Azithromycin | 1 | 2020 | 47 | 0.040 |
Why?
|
| Soaps | 1 | 2020 | 8 | 0.040 |
Why?
|
| HIV Infections | 1 | 1992 | 2068 | 0.040 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 3085 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2003 | 562 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 2001 | 157 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2009 | 1000 | 0.040 |
Why?
|
| Pharmacists | 1 | 2020 | 99 | 0.040 |
Why?
|
| Analysis of Variance | 3 | 2011 | 1045 | 0.040 |
Why?
|
| Cancer Pain | 1 | 2019 | 27 | 0.040 |
Why?
|
| Telephone | 1 | 2019 | 127 | 0.040 |
Why?
|
| Curriculum | 1 | 2024 | 771 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2022 | 604 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 1411 | 0.040 |
Why?
|
| Gift Giving | 1 | 2018 | 19 | 0.040 |
Why?
|
| Motivation | 2 | 2018 | 327 | 0.040 |
Why?
|
| Length of Stay | 3 | 2006 | 1383 | 0.040 |
Why?
|
| Conflict of Interest | 1 | 2018 | 69 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2019 | 455 | 0.030 |
Why?
|
| Pain Management | 1 | 2019 | 202 | 0.030 |
Why?
|
| Isocoumarins | 1 | 2016 | 2 | 0.030 |
Why?
|
| Coumarins | 1 | 2016 | 24 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 304 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 324 | 0.030 |
Why?
|
| Medical Records | 1 | 1997 | 193 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2010 | 850 | 0.030 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2016 | 44 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2003 | 881 | 0.030 |
Why?
|
| Disease | 1 | 1997 | 133 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 267 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2016 | 104 | 0.030 |
Why?
|
| Infection Control | 1 | 2016 | 152 | 0.030 |
Why?
|
| Geography | 1 | 2015 | 124 | 0.030 |
Why?
|
| Health Services | 1 | 1995 | 73 | 0.030 |
Why?
|
| Behavior | 1 | 2015 | 75 | 0.030 |
Why?
|
| Myocardial Revascularization | 1 | 1995 | 108 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2015 | 141 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2015 | 130 | 0.030 |
Why?
|
| Bias | 1 | 1995 | 147 | 0.030 |
Why?
|
| Insurance, Health | 1 | 1995 | 144 | 0.030 |
Why?
|
| Gram-Negative Bacteria | 1 | 2014 | 73 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 2016 | 276 | 0.030 |
Why?
|
| Educational Status | 1 | 2015 | 297 | 0.030 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 1995 | 184 | 0.030 |
Why?
|
| Cisplatin | 1 | 2015 | 287 | 0.030 |
Why?
|
| Disease Progression | 2 | 2010 | 2239 | 0.030 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2014 | 147 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 1569 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2006 | 604 | 0.030 |
Why?
|
| Levonorgestrel | 1 | 1992 | 21 | 0.020 |
Why?
|
| Family Planning Services | 1 | 1992 | 40 | 0.020 |
Why?
|
| APACHE | 3 | 1999 | 57 | 0.020 |
Why?
|
| Attitude | 1 | 1992 | 122 | 0.020 |
Why?
|
| Time and Motion Studies | 1 | 2011 | 22 | 0.020 |
Why?
|
| Coronary Disease | 1 | 1995 | 721 | 0.020 |
Why?
|
| Prognosis | 2 | 2011 | 5076 | 0.020 |
Why?
|
| Insurance Claim Reporting | 1 | 2010 | 8 | 0.020 |
Why?
|
| Workflow | 1 | 2011 | 133 | 0.020 |
Why?
|
| Patient Care | 1 | 2011 | 100 | 0.020 |
Why?
|
| Pulmonary Medicine | 1 | 2010 | 26 | 0.020 |
Why?
|
| Utilization Review | 1 | 2009 | 40 | 0.020 |
Why?
|
| Health Services Misuse | 1 | 2009 | 28 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 300 | 0.020 |
Why?
|
| Asthma | 1 | 2016 | 815 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 414 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2009 | 330 | 0.020 |
Why?
|
| Serotonin Antagonists | 1 | 2008 | 24 | 0.020 |
Why?
|
| Age of Onset | 1 | 2010 | 636 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 1995 | 889 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2011 | 660 | 0.020 |
Why?
|
| Age Distribution | 1 | 2009 | 444 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 743 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 756 | 0.020 |
Why?
|
| Child | 2 | 2019 | 25763 | 0.020 |
Why?
|
| Observer Variation | 2 | 1999 | 312 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2010 | 987 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2019 | 8592 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 1735 | 0.010 |
Why?
|
| Anti-Ulcer Agents | 1 | 2005 | 116 | 0.010 |
Why?
|
| Animals | 1 | 2006 | 36412 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2009 | 569 | 0.010 |
Why?
|
| Schizophrenia | 1 | 2008 | 332 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 1154 | 0.010 |
Why?
|
| Liver Diseases | 1 | 2009 | 390 | 0.010 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2006 | 194 | 0.010 |
Why?
|
| Infant | 1 | 2019 | 13174 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 1971 | 0.010 |
Why?
|
| Patient Selection | 1 | 2007 | 732 | 0.010 |
Why?
|
| Mass Screening | 1 | 2009 | 834 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2019 | 14806 | 0.010 |
Why?
|
| Potassium | 1 | 2003 | 290 | 0.010 |
Why?
|
| Total Quality Management | 1 | 2001 | 27 | 0.010 |
Why?
|
| Intermittent Claudication | 1 | 2002 | 60 | 0.010 |
Why?
|
| Anxiety | 1 | 2008 | 991 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2002 | 429 | 0.010 |
Why?
|
| Southwestern United States | 1 | 1999 | 48 | 0.010 |
Why?
|
| Medical History Taking | 1 | 1999 | 118 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 1999 | 454 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 1334 | 0.010 |
Why?
|
| Medical Audit | 1 | 1997 | 101 | 0.010 |
Why?
|
| Facility Regulation and Control | 1 | 1995 | 1 | 0.010 |
Why?
|
| Least-Squares Analysis | 1 | 1995 | 36 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2003 | 917 | 0.010 |
Why?
|
| Medically Uninsured | 1 | 1995 | 76 | 0.010 |
Why?
|
| Cardiac Output, Low | 1 | 1995 | 68 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2006 | 3160 | 0.010 |
Why?
|
| Program Development | 1 | 1994 | 190 | 0.010 |
Why?
|
| Delphi Technique | 1 | 1994 | 243 | 0.010 |
Why?
|
| Drug Implants | 1 | 1992 | 43 | 0.010 |
Why?
|
| Condoms | 1 | 1992 | 51 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 1992 | 125 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1997 | 2163 | 0.010 |
Why?
|
| Patient Care Team | 1 | 1994 | 572 | 0.010 |
Why?
|